LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 18

Search options

  1. Article: Target-driven machine learning-enabled virtual screening (TAME-VS) platform for early-stage hit identification.

    Bian, Yuemin / Kwon, Jason J / Liu, Cong / Margiotta, Enrico / Shekhar, Mrinal / Gould, Alexandra E

    Frontiers in molecular biosciences

    2023  Volume 10, Page(s) 1163536

    Abstract: High-throughput screening (HTS) methods enable the empirical evaluation of a large scale of compounds and can be augmented by virtual screening (VS) techniques to save time and money by using potential active compounds for experimental testing. Structure- ...

    Abstract High-throughput screening (HTS) methods enable the empirical evaluation of a large scale of compounds and can be augmented by virtual screening (VS) techniques to save time and money by using potential active compounds for experimental testing. Structure-based and ligand-based virtual screening approaches have been extensively studied and applied in drug discovery practice with proven outcomes in advancing candidate molecules. However, the experimental data required for VS are expensive, and hit identification in an effective and efficient manner is particularly challenging during early-stage drug discovery for novel protein targets. Herein, we present our TArget-driven Machine learning-Enabled VS (TAME-VS) platform, which leverages existing chemical databases of bioactive molecules to modularly facilitate hit finding. Our methodology enables bespoke hit identification campaigns through a user-defined protein target. The input target ID is used to perform a homology-based target expansion, followed by compound retrieval from a large compilation of molecules with experimentally validated activity. Compounds are subsequently vectorized and adopted for machine learning (ML) model training. These machine learning models are deployed to perform model-based inferential virtual screening, and compounds are nominated based on predicted activity. Our platform was retrospectively validated across ten diverse protein targets and demonstrated clear predictive power. The implemented methodology provides a flexible and efficient approach that is accessible to a wide range of users. The TAME-VS platform is publicly available at https://github.com/bymgood/Target-driven-ML-enabled-VS to facilitate early-stage hit identification.
    Language English
    Publishing date 2023-03-13
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2814330-9
    ISSN 2296-889X
    ISSN 2296-889X
    DOI 10.3389/fmolb.2023.1163536
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Susceptibilities of Ugandan Plasmodium falciparum Isolates to Proteasome Inhibitors.

    Garg, Shreeya / Kreutzfeld, Oriana / Chelebieva, Sevil / Tumwebaze, Patrick K / Byaruhanga, Oswald / Okitwi, Martin / Orena, Stephen / Katairo, Thomas / Nsobya, Samuel L / Conrad, Melissa D / Aydemir, Ozkan / Legac, Jennifer / Gould, Alexandra E / Bayles, Brett R / Bailey, Jeffrey A / Duffey, Maelle / Lin, Gang / Kirkman, Laura A / Cooper, Roland A /
    Rosenthal, Philip J

    Antimicrobial agents and chemotherapy

    2022  Volume 66, Issue 10, Page(s) e0081722

    Abstract: The proteasome is a promising target for antimalarial chemotherapy. We ... ...

    Abstract The proteasome is a promising target for antimalarial chemotherapy. We assessed
    MeSH term(s) Humans ; Antimalarials/pharmacology ; Antimalarials/chemistry ; Asparagine ; Drug Resistance/genetics ; Ethylenediamines/pharmacology ; Malaria, Falciparum/drug therapy ; Malaria, Falciparum/parasitology ; Peptides/pharmacology ; Plasmodium falciparum/drug effects ; Plasmodium falciparum/genetics ; Proteasome Endopeptidase Complex/genetics ; Proteasome Inhibitors/chemistry ; Proteasome Inhibitors/pharmacology ; Uganda
    Chemical Substances Antimalarials ; Asparagine (7006-34-0) ; divinyl sulfone (5PFN71LP8M) ; Ethylenediamines ; Peptides ; Proteasome Endopeptidase Complex (EC 3.4.25.1) ; Proteasome Inhibitors
    Language English
    Publishing date 2022-09-12
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 217602-6
    ISSN 1098-6596 ; 0066-4804
    ISSN (online) 1098-6596
    ISSN 0066-4804
    DOI 10.1128/aac.00817-22
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Mitigating the risk of antimalarial resistance via covalent dual-subunit inhibition of the Plasmodium proteasome.

    Deni, Ioanna / Stokes, Barbara H / Ward, Kurt E / Fairhurst, Kate J / Pasaje, Charisse Flerida A / Yeo, Tomas / Akbar, Shirin / Park, Heekuk / Muir, Ryan / Bick, Daniella S / Zhan, Wenhu / Zhang, Hao / Liu, Yi Jing / Ng, Caroline L / Kirkman, Laura A / Almaliti, Jehad / Gould, Alexandra E / Duffey, Maëlle / O'Donoghue, Anthony J /
    Uhlemann, Anne-Catrin / Niles, Jacquin C / da Fonseca, Paula C A / Gerwick, William H / Lin, Gang / Bogyo, Matthew / Fidock, David A

    Cell chemical biology

    2023  Volume 30, Issue 5, Page(s) 470–485.e6

    Abstract: The Plasmodium falciparum proteasome constitutes a promising antimalarial target, with multiple chemotypes potently and selectively inhibiting parasite proliferation and synergizing with the first-line artemisinin drugs, including against artemisinin- ... ...

    Abstract The Plasmodium falciparum proteasome constitutes a promising antimalarial target, with multiple chemotypes potently and selectively inhibiting parasite proliferation and synergizing with the first-line artemisinin drugs, including against artemisinin-resistant parasites. We compared resistance profiles of vinyl sulfone, epoxyketone, macrocyclic peptide, and asparagine ethylenediamine inhibitors and report that the vinyl sulfones were potent even against mutant parasites resistant to other proteasome inhibitors and did not readily select for resistance, particularly WLL that displays covalent and irreversible binding to the catalytic β2 and β5 proteasome subunits. We also observed instances of collateral hypersensitivity, whereby resistance to one inhibitor could sensitize parasites to distinct chemotypes. Proteasome selectivity was confirmed using CRISPR/Cas9-edited mutant and conditional knockdown parasites. Molecular modeling of proteasome mutations suggested spatial contraction of the β5 P1 binding pocket, compromising compound binding. Dual targeting of P. falciparum proteasome subunits using covalent inhibitors provides a potential strategy for restoring artemisinin activity and combating the spread of drug-resistant malaria.
    MeSH term(s) Humans ; Antimalarials/pharmacology ; Antimalarials/chemistry ; Proteasome Endopeptidase Complex/metabolism ; Plasmodium/metabolism ; Artemisinins/chemistry ; Malaria, Falciparum/drug therapy ; Malaria, Falciparum/parasitology ; Proteasome Inhibitors/pharmacology ; Proteasome Inhibitors/chemistry
    Chemical Substances Antimalarials ; Proteasome Endopeptidase Complex (EC 3.4.25.1) ; artemisinin (9RMU91N5K2) ; Artemisinins ; Proteasome Inhibitors
    Language English
    Publishing date 2023-03-23
    Publishing country United States
    Document type Journal Article ; Research Support, U.S. Gov't, Non-P.H.S. ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ISSN 2451-9448
    ISSN (online) 2451-9448
    DOI 10.1016/j.chembiol.2023.03.002
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Discovery and optimization of pyrazolopyrimidine sulfamates as ATG7 inhibitors.

    Huang, Shih-Chung / Adhikari, Sharmila / Brownell, James E / Calderwood, Emily F / Chouitar, Jouhara / D'Amore, Natalie Roy / England, Dylan B / Foley, Klaudia / Harrison, Sean J / LeRoy, Patrick J / Lok, David / Lublinsky, Anna / Ma, Li-Ting / Menon, Saurabh / Yang, Yu / Zhang, Ji / Gould, Alexandra E

    Bioorganic & medicinal chemistry

    2020  Volume 28, Issue 19, Page(s) 115681

    Abstract: Autophagy is postulated to be required by cancer cells to survive periods of metabolic and/or hypoxic stress. ATG7 is the E1 enzyme that is required for activation of Ubl conjugation pathways involved in autophagosome formation. This article describes ... ...

    Abstract Autophagy is postulated to be required by cancer cells to survive periods of metabolic and/or hypoxic stress. ATG7 is the E1 enzyme that is required for activation of Ubl conjugation pathways involved in autophagosome formation. This article describes the design and optimization of pyrazolopyrimidine sulfamate compounds as potent and selective inhibitors of ATG7. Cellular levels of the autophagy markers, LC3B and NBR1, are regulated following treatment with these compounds.
    MeSH term(s) Autophagy/drug effects ; Autophagy-Related Protein 7/antagonists & inhibitors ; Autophagy-Related Protein 7/metabolism ; Dose-Response Relationship, Drug ; Drug Discovery ; HEK293 Cells ; Humans ; Molecular Structure ; Pyrazoles/chemical synthesis ; Pyrazoles/chemistry ; Pyrazoles/pharmacology ; Pyrimidines/chemical synthesis ; Pyrimidines/chemistry ; Pyrimidines/pharmacology ; Structure-Activity Relationship ; Sulfonic Acids/chemical synthesis ; Sulfonic Acids/chemistry ; Sulfonic Acids/pharmacology
    Chemical Substances Pyrazoles ; Pyrimidines ; Sulfonic Acids ; pyrazolylpyrimidine ; sulfamic acid (9NFU33906Q) ; ATG7 protein, human (EC 6.2.1.45) ; Autophagy-Related Protein 7 (EC 6.2.1.45)
    Language English
    Publishing date 2020-08-04
    Publishing country England
    Document type Journal Article
    ZDB-ID 1161284-8
    ISSN 1464-3391 ; 0968-0896
    ISSN (online) 1464-3391
    ISSN 0968-0896
    DOI 10.1016/j.bmc.2020.115681
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Discovery of mobocertinib, a potent, oral inhibitor of EGFR exon 20 insertion mutations in non-small cell lung cancer.

    Huang, Wei-Sheng / Li, Feng / Gong, Yongjin / Zhang, Yun / Youngsaye, Willmen / Xu, Yongjin / Zhu, Xiaotian / Greenfield, Matthew T / Kohlmann, Anna / Taslimi, Paul M / Toms, Angela / Zech, Stephan G / Zhou, Tianjun / Das, Biplab / Jang, Hyun G / Tugnait, Meera / Ye, Yihua E / Gonzalvez, Francois / Baker, Theresa E /
    Nadworny, Sara / Ning, Yaoyu / Wardwell, Scott D / Zhang, Sen / Gould, Alexandra E / Hu, Yongbo / Lane, Weston / Skene, Robert J / Zou, Hua / Clackson, Tim / Narasimhan, Narayana I / Rivera, Victor M / Dalgarno, David C / Shakespeare, William C

    Bioorganic & medicinal chemistry letters

    2022  Volume 80, Page(s) 129084

    Abstract: In the treatment of non-small cell lung cancer (NSCLC), patients harboring exon 20 insertion mutations in the epidermal growth factor receptor (EGFR) gene (EGFR) have few effective therapies because this subset of mutants is generally resistant to most ... ...

    Abstract In the treatment of non-small cell lung cancer (NSCLC), patients harboring exon 20 insertion mutations in the epidermal growth factor receptor (EGFR) gene (EGFR) have few effective therapies because this subset of mutants is generally resistant to most currently approved EGFR inhibitors. This report describes the structure-guided design of a novel series of potent, irreversible inhibitors of EGFR exon 20 insertion mutations, including the V769_D770insASV and D770_N771insSVD mutants. Extensive structure-activity relationship (SAR) studies led to the discovery of mobocertinib (compound 21c), which inhibited growth of Ba/F3 cells expressing the ASV insertion with a half-maximal inhibitory concentration of 11 nM and with selectivity over wild-type EGFR. Daily oral administration of mobocertinib induced tumor regression in a Ba/F3 ASV xenograft mouse model at well-tolerated doses. Mobocertinib was approved in September 2021 for the treatment of adult patients with advanced NSCLC with EGFR exon 20 insertion mutations with progression on or after platinum-based chemotherapy.
    MeSH term(s) Humans ; Mice ; Animals ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/pathology ; Lung Neoplasms/drug therapy ; Lung Neoplasms/genetics ; Lung Neoplasms/pathology ; Mutagenesis, Insertional ; Mutation ; ErbB Receptors ; Exons ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use
    Chemical Substances mobocertinib ; ErbB Receptors (EC 2.7.10.1) ; Protein Kinase Inhibitors ; EGFR protein, human (EC 2.7.10.1)
    Language English
    Publishing date 2022-11-21
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1063195-1
    ISSN 1464-3405 ; 0960-894X
    ISSN (online) 1464-3405
    ISSN 0960-894X
    DOI 10.1016/j.bmcl.2022.129084
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Mobocertinib (TAK-788): A Targeted Inhibitor of

    Gonzalvez, Francois / Vincent, Sylvie / Baker, Theresa E / Gould, Alexandra E / Li, Shuai / Wardwell, Scott D / Nadworny, Sara / Ning, Yaoyu / Zhang, Sen / Huang, Wei-Sheng / Hu, Yongbo / Li, Feng / Greenfield, Matthew T / Zech, Stephan G / Das, Biplab / Narasimhan, Narayana I / Clackson, Tim / Dalgarno, David / Shakespeare, William C /
    Fitzgerald, Michael / Chouitar, Johara / Griffin, Robert J / Liu, Shengwu / Wong, Kwok-Kin / Zhu, Xiaotian / Rivera, Victor M

    Cancer discovery

    2021  Volume 11, Issue 7, Page(s) 1672–1687

    Abstract: ... ...

    Abstract Most
    MeSH term(s) Aniline Compounds/pharmacology ; Aniline Compounds/therapeutic use ; Animals ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/genetics ; Cell Line, Tumor/drug effects ; ErbB Receptors ; Exons ; Humans ; Indoles/pharmacology ; Indoles/therapeutic use ; Lung Neoplasms/drug therapy ; Lung Neoplasms/genetics ; Mice ; Mutagenesis, Insertional ; Pyrimidines/pharmacology ; Pyrimidines/therapeutic use ; Xenograft Model Antitumor Assays
    Chemical Substances Aniline Compounds ; Antineoplastic Agents ; Indoles ; Pyrimidines ; mobocertinib ; EGFR protein, human (EC 2.7.10.1) ; ErbB Receptors (EC 2.7.10.1)
    Language English
    Publishing date 2021-02-25
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2625242-9
    ISSN 2159-8290 ; 2159-8274
    ISSN (online) 2159-8290
    ISSN 2159-8274
    DOI 10.1158/2159-8290.CD-20-1683
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Reaction hijacking of tyrosine tRNA synthetase as a new whole-of-life-cycle antimalarial strategy.

    Xie, Stanley C / Metcalfe, Riley D / Dunn, Elyse / Morton, Craig J / Huang, Shih-Chung / Puhalovich, Tanya / Du, Yawei / Wittlin, Sergio / Nie, Shuai / Luth, Madeline R / Ma, Liting / Kim, Mi-Sook / Pasaje, Charisse Flerida A / Kumpornsin, Krittikorn / Giannangelo, Carlo / Houghton, Fiona J / Churchyard, Alisje / Famodimu, Mufuliat T / Barry, Daniel C /
    Gillett, David L / Dey, Sumanta / Kosasih, Clara C / Newman, William / Niles, Jacquin C / Lee, Marcus C S / Baum, Jake / Ottilie, Sabine / Winzeler, Elizabeth A / Creek, Darren J / Williamson, Nicholas / Parker, Michael W / Brand, Stephen / Langston, Steven P / Dick, Lawrence R / Griffin, Michael D W / Gould, Alexandra E / Tilley, Leann

    Science (New York, N.Y.)

    2022  Volume 376, Issue 6597, Page(s) 1074–1079

    Abstract: Aminoacyl transfer RNA (tRNA) synthetases (aaRSs) are attractive drug targets, and we present class I and II aaRSs as previously unrecognized targets for adenosine 5'-monophosphate-mimicking nucleoside sulfamates. The target enzyme catalyzes the ... ...

    Abstract Aminoacyl transfer RNA (tRNA) synthetases (aaRSs) are attractive drug targets, and we present class I and II aaRSs as previously unrecognized targets for adenosine 5'-monophosphate-mimicking nucleoside sulfamates. The target enzyme catalyzes the formation of an inhibitory amino acid-sulfamate conjugate through a reaction-hijacking mechanism. We identified adenosine 5'-sulfamate as a broad-specificity compound that hijacks a range of aaRSs and ML901 as a specific reagent a specific reagent that hijacks a single aaRS in the malaria parasite
    MeSH term(s) Adenosine/analogs & derivatives ; Animals ; Antimalarials/chemistry ; Antimalarials/pharmacology ; Antimalarials/therapeutic use ; Crystallography, X-Ray ; Humans ; Malaria, Falciparum/drug therapy ; Malaria, Falciparum/parasitology ; Mice ; Molecular Targeted Therapy ; Plasmodium falciparum/drug effects ; Plasmodium falciparum/enzymology ; Protein Biosynthesis/drug effects ; Protein Conformation ; Protozoan Proteins/chemistry ; Protozoan Proteins/metabolism ; Sulfonic Acids/chemistry ; Tyrosine-tRNA Ligase/chemistry ; Tyrosine-tRNA Ligase/metabolism
    Chemical Substances Antimalarials ; Protozoan Proteins ; Sulfonic Acids ; sulfamic acid (9NFU33906Q) ; Tyrosine-tRNA Ligase (EC 6.1.1.1) ; Adenosine (K72T3FS567)
    Language English
    Publishing date 2022-06-02
    Publishing country United States
    Document type Journal Article
    ZDB-ID 128410-1
    ISSN 1095-9203 ; 0036-8075
    ISSN (online) 1095-9203
    ISSN 0036-8075
    DOI 10.1126/science.abn0611
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Target Validation and Identification of Novel Boronate Inhibitors of the Plasmodium falciparum Proteasome.

    Xie, Stanley C / Gillett, David L / Spillman, Natalie J / Tsu, Christopher / Luth, Madeline R / Ottilie, Sabine / Duffy, Sandra / Gould, Alexandra E / Hales, Paul / Seager, Benjamin A / Charron, Carlie L / Bruzzese, Frank / Yang, Xiaofeng / Zhao, Xiansi / Huang, Shih-Chung / Hutton, Craig A / Burrows, Jeremy N / Winzeler, Elizabeth A / Avery, Vicky M /
    Dick, Lawrence R / Tilley, Leann

    Journal of medicinal chemistry

    2018  Volume 61, Issue 22, Page(s) 10053–10066

    Abstract: The Plasmodium proteasome represents a potential antimalarial drug target for compounds with activity against multiple life cycle stages. We screened a library of human proteasome inhibitors (peptidyl boronic acids) and compared activities against ... ...

    Abstract The Plasmodium proteasome represents a potential antimalarial drug target for compounds with activity against multiple life cycle stages. We screened a library of human proteasome inhibitors (peptidyl boronic acids) and compared activities against purified P. falciparum and human 20S proteasomes. We chose four hits that potently inhibit parasite growth and show a range of selectivities for inhibition of the growth of P. falciparum compared with human cell lines. P. falciparum was selected for resistance in vitro to the clinically used proteasome inhibitor, bortezomib, and whole genome sequencing was applied to identify mutations in the proteasome β5 subunit. Active site profiling revealed inhibitor features that enable retention of potent activity against the bortezomib-resistant line. Substrate profiling reveals P. falciparum 20S proteasome active site preferences that will inform attempts to design more selective inhibitors. This work provides a starting point for the identification of antimalarial drug leads that selectively target the P. falciparum proteasome.
    MeSH term(s) Amino Acid Sequence ; Animals ; Boronic Acids/chemistry ; Boronic Acids/pharmacology ; Catalytic Domain ; Cell Line ; Drug Design ; Drug Evaluation, Preclinical ; Drug Resistance/drug effects ; Humans ; Models, Molecular ; Plasmodium falciparum/enzymology ; Proteasome Endopeptidase Complex/chemistry ; Proteasome Endopeptidase Complex/metabolism ; Proteasome Inhibitors/chemistry ; Proteasome Inhibitors/pharmacology
    Chemical Substances Boronic Acids ; Proteasome Inhibitors ; Proteasome Endopeptidase Complex (EC 3.4.25.1)
    Language English
    Publishing date 2018-11-07
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 218133-2
    ISSN 1520-4804 ; 0022-2623
    ISSN (online) 1520-4804
    ISSN 0022-2623
    DOI 10.1021/acs.jmedchem.8b01161
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Discovery and optimization of N-acyl and N-aroylpyrazolines as B-Raf kinase inhibitors.

    Blackburn, Christopher / Duffey, Matthew O / Gould, Alexandra E / Kulkarni, Bheemashankar / Liu, Jane X / Menon, Saurabh / Nagayoshi, Masayuki / Vos, Tricia J / Williams, Juliet

    Bioorganic & medicinal chemistry letters

    2010  Volume 20, Issue 16, Page(s) 4795–4799

    Abstract: A high throughput screen identified N-aroylpyrazoline 1 as a selective inhibitor of the V600E mutant of B-Raf kinase. Parallel synthesis of acyl, aroyl, and sulfonyl derivatives led to the identification of several potent inhibitors in both enzymatic and ...

    Abstract A high throughput screen identified N-aroylpyrazoline 1 as a selective inhibitor of the V600E mutant of B-Raf kinase. Parallel synthesis of acyl, aroyl, and sulfonyl derivatives led to the identification of several potent inhibitors in both enzymatic and cellular (pERK) assays such as compound 42.
    MeSH term(s) Amino Acid Substitution ; Drug Evaluation, Preclinical ; High-Throughput Screening Assays ; Protein Kinase Inhibitors/chemical synthesis ; Protein Kinase Inhibitors/chemistry ; Protein Kinase Inhibitors/pharmacology ; Proto-Oncogene Proteins B-raf/antagonists & inhibitors ; Proto-Oncogene Proteins B-raf/genetics ; Proto-Oncogene Proteins B-raf/metabolism ; Pyrazoles/chemical synthesis ; Pyrazoles/chemistry ; Pyrazoles/pharmacology ; Pyridines/chemical synthesis ; Pyridines/chemistry ; Pyridines/pharmacology ; Recombinant Proteins/antagonists & inhibitors ; Recombinant Proteins/genetics ; Recombinant Proteins/metabolism ; Structure-Activity Relationship
    Chemical Substances Protein Kinase Inhibitors ; Pyrazoles ; Pyridines ; Recombinant Proteins ; Proto-Oncogene Proteins B-raf (EC 2.7.11.1)
    Language English
    Publishing date 2010-08-15
    Publishing country England
    Document type Journal Article
    ZDB-ID 1063195-1
    ISSN 1464-3405 ; 0960-894X
    ISSN (online) 1464-3405
    ISSN 0960-894X
    DOI 10.1016/j.bmcl.2010.06.110
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Design of proteasome inhibitors with oral efficacy in vivo against

    Xie, Stanley C / Metcalfe, Riley D / Mizutani, Hirotake / Puhalovich, Tanya / Hanssen, Eric / Morton, Craig J / Du, Yawei / Dogovski, Con / Huang, Shih-Chung / Ciavarri, Jeffrey / Hales, Paul / Griffin, Robert J / Cohen, Lawrence H / Chuang, Bei-Ching / Wittlin, Sergio / Deni, Ioanna / Yeo, Tomas / Ward, Kurt E / Barry, Daniel C /
    Liu, Boyin / Gillett, David L / Crespo-Fernandez, Benigno F / Ottilie, Sabine / Mittal, Nimisha / Churchyard, Alisje / Ferguson, Daniel / Aguiar, Anna Caroline C / Guido, Rafael V C / Baum, Jake / Hanson, Kirsten K / Winzeler, Elizabeth A / Gamo, Francisco-Javier / Fidock, David A / Baud, Delphine / Parker, Michael W / Brand, Stephen / Dick, Lawrence R / Griffin, Michael D W / Gould, Alexandra E / Tilley, Leann

    Proceedings of the National Academy of Sciences of the United States of America

    2021  Volume 118, Issue 39

    Abstract: ... ...

    Abstract The
    MeSH term(s) Administration, Oral ; Animals ; Boron Compounds/administration & dosage ; Boron Compounds/chemistry ; Boron Compounds/pharmacology ; Catalytic Domain ; Humans ; Malaria, Falciparum/drug therapy ; Malaria, Falciparum/enzymology ; Malaria, Falciparum/parasitology ; Mice ; Mice, Inbred NOD ; Mice, SCID ; Models, Molecular ; Plasmodium falciparum/drug effects ; Plasmodium falciparum/enzymology ; Proteasome Endopeptidase Complex/chemistry ; Proteasome Inhibitors/administration & dosage ; Proteasome Inhibitors/chemistry ; Proteasome Inhibitors/pharmacology
    Chemical Substances Boron Compounds ; Proteasome Inhibitors ; Proteasome Endopeptidase Complex (EC 3.4.25.1)
    Language English
    Publishing date 2021-09-30
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 209104-5
    ISSN 1091-6490 ; 0027-8424
    ISSN (online) 1091-6490
    ISSN 0027-8424
    DOI 10.1073/pnas.2107213118
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top